Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 400

1.

Combined effects of lung function, blood gases and kidney function on the exacerbation risk in stable COPD: Results from the COSYCONET cohort.

Trudzinski FC, Kahnert K, Vogelmeier CF, Alter P, Seiler F, Fähndrich S, Watz H, Welte T, Speer T, Zewinger S, Biertz F, Kauczor HU, Jörres RA, Bals R; COSYCONET consortium.

Respir Med. 2019 Jun 11;154:18-26. doi: 10.1016/j.rmed.2019.06.007. [Epub ahead of print]

PMID:
31203096
2.

Prevalence and Characteristics of Asthma-COPD Overlap in Routine Primary Care Practices.

Krishnan JA, Nibber A, Chisholm A, Price D, Bateman ED, Bjermer L, van Boven JF, Brusselle G, Costello RW, Dandurand RJ, Diamant Z, Van Ganse E, Gouder C, van Kampen SC, Kaplan A, Kocks J, Miravitlles M, Niimi A, Pizzichini E, Rhee CK, Soriano JB, Vogelmeier C, Román-Rodriguez M, Carter V, Roche N.

Ann Am Thorac Soc. 2019 Jun 4. doi: 10.1513/AnnalsATS.201809-607OC. [Epub ahead of print]

PMID:
31162945
3.

Inhaled corticosteroid use by exacerbations and eosinophils: a real-world COPD population.

Vestbo J, Vogelmeier CF, Small M, Siddall J, Fogel R, Kostikas K.

Int J Chron Obstruct Pulmon Dis. 2019 Apr 16;14:853-861. doi: 10.2147/COPD.S189585. eCollection 2019.

4.

Benralizumab for the Prevention of COPD Exacerbations.

Criner GJ, Celli BR, Brightling CE, Agusti A, Papi A, Singh D, Sin DD, Vogelmeier CF, Sciurba FC, Bafadhel M, Backer V, Kato M, Ramírez-Venegas A, Wei YF, Bjermer L, Shih VH, Jison M, O'Quinn S, Makulova N, Newbold P, Goldman M, Martin UJ; GALATHEA and TERRANOVA Study Investigators.

N Engl J Med. 2019 May 20. doi: 10.1056/NEJMoa1905248. [Epub ahead of print]

PMID:
31112385
5.

["Digitalization in Internal Medicine" - not "Digitalization of Internal Medicine" - a Promising Perspective from Non-Digital Natives].

Vogelmeier CF, Köhler F.

Dtsch Med Wochenschr. 2019 Apr;144(7):425. doi: 10.1055/a-0746-5964. Epub 2019 Mar 29. German. No abstract available.

PMID:
30925594
6.

[Digital medicine].

Hasenfuß G, Vogelmeier CF.

Internist (Berl). 2019 Apr;60(4):317-318. doi: 10.1007/s00108-019-0594-7. German. No abstract available.

PMID:
30923862
7.

Effects of airway obstruction and hyperinflation on electrocardiographic axes in COPD.

Alter P, Watz H, Kahnert K, Rabe KF, Biertz F, Fischer R, Jung P, Graf J, Bals R, Vogelmeier CF, Jörres RA.

Respir Res. 2019 Mar 27;20(1):61. doi: 10.1186/s12931-019-1025-y.

8.

[Orphan drugs].

Schäfer JR, Vogelmeier CF.

Internist (Berl). 2019 Apr;60(4):396-398. doi: 10.1007/s00108-019-0582-y. German. No abstract available.

PMID:
30859277
9.

Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: the GOLD science committee report 2019.

Singh D, Agusti A, Anzueto A, Barnes PJ, Bourbeau J, Celli BR, Criner GJ, Frith P, Halpin DMG, Han M, López Varela MV, Martinez F, Montes de Oca M, Papi A, Pavord ID, Roche N, Sin DD, Stockley R, Vestbo J, Wedzicha JA, Vogelmeier C.

Eur Respir J. 2019 May 18;53(5). pii: 1900164. doi: 10.1183/13993003.00164-2019. Print 2019 May. Review.

PMID:
30846476
10.

Treatment response in COPD: does FEV1 say it all? A post hoc analysis of the CRYSTAL study.

Kostikas K, Greulich T, Mackay AJ, Lossi NS, Aalamian-Mattheis M, Nunez X, Pagano VA, Patalano F, Clemens A, Vogelmeier CF.

ERJ Open Res. 2019 Feb 25;5(1). pii: 00243-2018. doi: 10.1183/23120541.00243-2018. eCollection 2019 Feb.

11.

Artificial intelligence outperforms pulmonologists in the interpretation of pulmonary function tests.

Topalovic M, Das N, Burgel PR, Daenen M, Derom E, Haenebalcke C, Janssen R, Kerstjens HAM, Liistro G, Louis R, Ninane V, Pison C, Schlesser M, Vercauter P, Vogelmeier CF, Wouters E, Wynants J, Janssens W; Pulmonary Function Study Investigators; Pulmonary Function Study Investigators:.

Eur Respir J. 2019 Apr 11;53(4). pii: 1801660. doi: 10.1183/13993003.01660-2018. Print 2019 Apr.

PMID:
30765505
12.

Effect of COPD severity and comorbidities on the result of the PHQ-9 tool for the diagnosis of depression: results from the COSYCONET cohort study.

von Siemens SM, Jörres RA, Behr J, Alter P, Lutter J, Lucke T, Söhler S, Welte T, Watz H, Vogelmeier CF, Trudzinski F, Rief W, Herbig B, Kahnert K; COSYCONET study group.

Respir Res. 2019 Feb 11;20(1):30. doi: 10.1186/s12931-019-0997-y.

13.

[Perspectives 2025 - Positions of the German Society of Internal Medicine].

Vogelmeier C, Floege J, Gamstätter T.

Dtsch Med Wochenschr. 2019 Feb;144(3):207-212. doi: 10.1055/a-0799-5146. Epub 2019 Jan 31. German.

PMID:
30703843
14.

Spirometric changes during exacerbations of COPD: a post hoc analysis of the WISDOM trial.

Watz H, Tetzlaff K, Magnussen H, Mueller A, Rodriguez-Roisin R, Wouters EFM, Vogelmeier C, Calverley PMA.

Respir Res. 2018 Dec 13;19(1):251. doi: 10.1186/s12931-018-0944-3.

15.

Current Controversies in Chronic Obstructive Pulmonary Disease. A Report from the Global Initiative for Chronic Obstructive Lung Disease Scientific Committee.

Criner GJ, Martinez FJ, Aaron S, Agusti A, Anzueto A, Bafadhel M, Barnes PJ, Bourbeau J, Chen R, Ewig J, Fabbri LM, Frith P, Halpin DMG, Han M, Montes de Oca M, Nishimura M, O'Donnell D, Papi A, Pavord I, Roche N, Rodriguez-Roisin R, Salvi S, Singh D, Sin DD, Stockley R, López Varela MV, Vestbo J, Vogelmeier CF, Washko G, Wedzicha JA, Celli BR.

Ann Am Thorac Soc. 2019 Jan;16(1):29-39. doi: 10.1513/AnnalsATS.201808-557PS. No abstract available.

PMID:
30427736
16.

[Guideline for the Diagnosis and Treatment of Asthma - Guideline of the German Respiratory Society and the German Atemwegsliga in Cooperation with the Paediatric Respiratory Society and the Austrian Society of Pneumology].

Buhl R, Bals R, Baur X, Berdel D, Criée CP, Gappa M, Gillissen A, Greulich T, Haidl P, Hamelmann E, Kardos P, Kenn K, Klimek L, Korn S, Lommatzsch M, Magnussen H, Nicolai T, Nowak D, Pfaar O, Rabe KF, Riedler J, Ritz T, Schultz K, Schuster A, Spindler T, Taube C, Taube K, Vogelmeier C, von Leupoldt A, Wantke F, Weise S, Wildhaber J, Worth H, Zacharasiewicz A.

Pneumologie. 2017 Dec;71(12):e3. doi: 10.1055/a-0790-0021. Epub 2018 Nov 7. German. No abstract available.

PMID:
30406626
17.

The LEAD (Lung, Heart, Social, Body) Study: Objectives, Methodology, and External Validity of the Population-Based Cohort Study.

Breyer-Kohansal R, Hartl S, Burghuber OC, Urban M, Schrott A, Agusti A, Sigsgaard T, Vogelmeier C, Wouters E, Studnicka M, Breyer MK.

J Epidemiol. 2018 Oct 20. doi: 10.2188/jea.JE20180039. [Epub ahead of print]

18.

Longitudinal stability of blood eosinophil count strata in the COPD COSYCONET cohort.

Greulich T, Mager S, Lucke T, Koczulla AR, Bals R, Fähndrich S, Jörres RA, Alter P, Kirsten A, Vogelmeier CF, Watz H.

Int J Chron Obstruct Pulmon Dis. 2018 Sep 28;13:2999-3002. doi: 10.2147/COPD.S165909. eCollection 2018. No abstract available.

19.

Medical Treatment of COPD.

Graf J, Jörres RA, Lucke T, Nowak D, Vogelmeier CF, Ficker JH.

Dtsch Arztebl Int. 2018 Sep 14;155(37):599-605. doi: 10.3238/arztebl.2018.0599.

20.

Proviral MicroRNAs Detected in Extracellular Vesicles From Bronchoalveolar Lavage Fluid of Patients With Influenza Virus-Induced Acute Respiratory Distress Syndrome.

Scheller N, Herold S, Kellner R, Bertrams W, Jung AL, Janga H, Greulich T, Schulte LN, Vogelmeier CF, Lohmeyer J, Schmeck B.

J Infect Dis. 2019 Jan 29;219(4):540-543. doi: 10.1093/infdis/jiy554.

PMID:
30239899
21.

Safety of biweekly α1-antitrypsin treatment in the RAPID programme.

Greulich T, Chlumsky J, Wencker M, Vit O, Fries M, Chung T, Shebl A, Vogelmeier C, Chapman KR, McElvaney NG; RAPID Trial Group.

Eur Respir J. 2018 Nov 29;52(5). pii: 1800897. doi: 10.1183/13993003.00897-2018. Print 2018 Nov. No abstract available.

22.

[Control of Respiratory Symptoms During Sleep in Patients with Stable Bronchial Asthma].

Guenter K, Cassel W, Hildebrandt O, Kroenig J, Fischer P, Weissflog A, Vogelmeier C, Koehler U.

Dtsch Med Wochenschr. 2018 Sep;143(18):e159-e164. doi: 10.1055/a-0623-8651. Epub 2018 Sep 10. German.

PMID:
30199906
23.

Dual bronchodilation vs triple therapy in the "real-life" COPD DACCORD study.

Buhl R, Criée CP, Kardos P, Vogelmeier CF, Kostikas K, Lossi NS, Worth H.

Int J Chron Obstruct Pulmon Dis. 2018 Aug 24;13:2557-2568. doi: 10.2147/COPD.S169958. eCollection 2018.

24.

Influence of body mass on predicted values of static hyperinflation in COPD.

Alter P, Rabe KF, Schulz H, Vogelmeier CF, Jörres RA.

Int J Chron Obstruct Pulmon Dis. 2018 Aug 23;13:2551-2555. doi: 10.2147/COPD.S164096. eCollection 2018.

25.

COPD as a risk factor of the complications in lower limb arthroplasty: a patient-matched study.

Klasan A, Dworschak P, Heyse TJ, Ruchholtz S, Alter P, Vogelmeier CF, Schwarz P.

Int J Chron Obstruct Pulmon Dis. 2018 Aug 21;13:2495-2499. doi: 10.2147/COPD.S161577. eCollection 2018.

26.

[The lung in systemic diseases : Between holistic and individualized medicine-a challenge for internal medicine].

Welte T, Vogelmeier C, Hiddemann W, Märker-Hermann E.

Internist (Berl). 2018 Sep;59(9):873-875. doi: 10.1007/s00108-018-0481-7. German. No abstract available.

PMID:
30143815
27.

Real world evaluation of a novel lateral flow assay (AlphaKit® QuickScreen) for the detection of alpha-1-antitrypsin deficiency.

Greulich T, Rodríguez-Frias F, Belmonte I, Klemmer A, Vogelmeier CF, Miravitlles M.

Respir Res. 2018 Aug 13;19(1):151. doi: 10.1186/s12931-018-0826-8.

28.

[Antibiotics: The Most Important Discovery in Medicine of the 20th Century].

Vogelmeier CF.

Dtsch Med Wochenschr. 2018 Aug;143(15):1057. doi: 10.1055/a-0606-1729. Epub 2018 Jul 30. German. No abstract available.

PMID:
30060272
29.

Genome-wide MicroRNA Expression Profiles in COPD: Early Predictors for Cancer Development.

Keller A, Fehlmann T, Ludwig N, Kahraman M, Laufer T, Backes C, Vogelmeier C, Diener C, Biertz F, Herr C, Jörres RA, Lenhof HP, Meese E, Bals R; COSYCONET Study Group.

Genomics Proteomics Bioinformatics. 2018 Jun;16(3):162-171. doi: 10.1016/j.gpb.2018.06.001. Epub 2018 Jul 5.

30.

Design and application of an MR reference phantom for multicentre lung imaging trials.

Triphan SMF, Biederer J, Burmester K, Fellhauer I, Vogelmeier CF, Jörres RA, Kauczor HU, Heußel CP, Wielpütz MO, Jobst BJ.

PLoS One. 2018 Jul 5;13(7):e0199148. doi: 10.1371/journal.pone.0199148. eCollection 2018.

31.

Uric acid, lung function, physical capacity and exacerbation frequency in patients with COPD: a multi-dimensional approach.

Kahnert K, Alter P, Welte T, Huber RM, Behr J, Biertz F, Watz H, Bals R, Vogelmeier CF, Jörres RA.

Respir Res. 2018 Jun 4;19(1):110. doi: 10.1186/s12931-018-0815-y.

32.

Health status in patients with COPD treated with roflumilast: two large noninterventional real-life studies: DINO and DACOTA.

Kardos P, Mokros I, Sauer R, Vogelmeier CF.

Int J Chron Obstruct Pulmon Dis. 2018 May 3;13:1455-1468. doi: 10.2147/COPD.S159827. eCollection 2018.

33.

Relationship of spirometric, body plethysmographic, and diffusing capacity parameters to emphysema scores derived from CT scans.

Kahnert K, Jobst B, Biertz F, Biederer J, Watz H, Huber RM, Behr J, Grenier PA, Alter P, Vogelmeier CF, Kauczor HU, Jörres RA.

Chron Respir Dis. 2019 Jan-Dec;16:1479972318775423. doi: 10.1177/1479972318775423. Epub 2018 May 9.

34.

Indacaterol/glycopyrronium reduces the risk of clinically important deterioration after direct switch from baseline therapies in patients with moderate COPD: a post hoc analysis of the CRYSTAL study.

Greulich T, Kostikas K, Gaga M, Aalamian-Mattheis M, Lossi NS, Patalano F, Nunez X, Pagano VA, Fogel R, Vogelmeier CF, Clemens A.

Int J Chron Obstruct Pulmon Dis. 2018 Apr 16;13:1229-1237. doi: 10.2147/COPD.S159732. eCollection 2018.

35.

Exacerbation heterogeneity in COPD: subgroup analyses from the FLAME study.

Vogelmeier CF, Chapman KR, Miravitlles M, Roche N, Vestbo J, Thach C, Banerji D, Fogel R, Patalano F, Olsson P, Kostikas K, Wedzicha JA.

Int J Chron Obstruct Pulmon Dis. 2018 Apr 10;13:1125-1134. doi: 10.2147/COPD.S160011. eCollection 2018.

36.

Pharmacological treatment of COPD: the devil is always in the detail.

Singh D, Barnes PJ, Stockley R, Lopez Valera MV, Vogelmeier C, Agusti A.

Eur Respir J. 2018 Apr 19;51(4). pii: 1800263. doi: 10.1183/13993003.00263-2018. Print 2018 Apr. No abstract available.

PMID:
29674480
37.

Left ventricular volume and wall stress are linked to lung function impairment in COPD.

Alter P, Jörres RA, Watz H, Welte T, Gläser S, Schulz H, Bals R, Karch A, Wouters EFM, Vestbo J, Young D, Vogelmeier CF.

Int J Cardiol. 2018 Jun 15;261:172-178. doi: 10.1016/j.ijcard.2018.02.074.

PMID:
29657040
38.

Blood eosinophils as a marker of eosinophilic exacerbations in COPD.

Greulich T, Vogelmeier CF.

Lancet Respir Med. 2018 May;6(5):e17. doi: 10.1016/S2213-2600(18)30095-X. Epub 2018 Apr 5. No abstract available.

PMID:
29627195
39.

A GATA3-specific DNAzyme attenuates sputum eosinophilia in eosinophilic COPD patients: a feasibility randomized clinical trial.

Greulich T, Hohlfeld JM, Neuser P, Lueer K, Klemmer A, Schade-Brittinger C, Harnisch S, Garn H, Renz H, Homburg U, Renz J, Kirsten A, Pedersen F, Müller M, Vogelmeier CF, Watz H.

Respir Res. 2018 Apr 4;19(1):55. doi: 10.1186/s12931-018-0751-x.

40.

Airway obstruction and lung hyperinflation in COPD are linked to an impaired left ventricular diastolic filling.

Alter P, Watz H, Kahnert K, Pfeifer M, Randerath WJ, Andreas S, Waschki B, Kleibrink BE, Welte T, Bals R, Schulz H, Biertz F, Young D, Vogelmeier CF, Jörres RA.

Respir Med. 2018 Apr;137:14-22. doi: 10.1016/j.rmed.2018.02.011. Epub 2018 Feb 19.

PMID:
29605197
41.

Exacerbations of COPD.

Viniol C, Vogelmeier CF.

Eur Respir Rev. 2018 Mar 14;27(147). pii: 170103. doi: 10.1183/16000617.0103-2017. Print 2018 Mar 31. Review.

42.

[Guideline for the Diagnosis and Treatment of COPD Patients - Issued by the German Respiratory Society and the German Atemwegsliga in Cooperation with the Austrian Society of Pneumology].

Vogelmeier C, Buhl R, Burghuber O, Criée CP, Ewig S, Godnic-Cvar J, Hartl S, Herth F, Kardos P, Kenn K, Nowak D, Rabe KF, Studnicka M, Watz H, Welte T, Windisch W, Worth H; unter Mitwirkung der folgenden wissenschaftlichen Fachgesellschaften: Deutsche Gesellschaft für Arbeitsmedizin und Umweltmedizin e.V. ; Deutsche Gesellschaft für Rehabilitationswissenschaften e.V.

Pneumologie. 2018 Apr;72(4):253-308. doi: 10.1055/s-0043-125031. Epub 2018 Mar 9. German.

PMID:
29523017
43.

Compatibility of medication with PRISCUS criteria and identification of drug interactions in a large cohort of patients with COPD.

Graf J, Lucke T, Herrera R, Watz H, Holle R, Vogelmeier C, Ficker JH, Jörres RA.

Pulm Pharmacol Ther. 2018 Apr;49:123-129. doi: 10.1016/j.pupt.2018.01.011. Epub 2018 Feb 5.

PMID:
29421666
44.

The revised GOLD 2017 COPD categorization in relation to comorbidities.

Kahnert K, Alter P, Young D, Lucke T, Heinrich J, Huber RM, Behr J, Wacker M, Biertz F, Watz H, Bals R, Welte T, Wirtz H, Herth F, Vestbo J, Wouters EF, Vogelmeier CF, Jörres RA.

Respir Med. 2018 Jan;134:79-85. doi: 10.1016/j.rmed.2017.12.003. Epub 2017 Dec 5.

45.

Chronic obstructive pulmonary disease guidelines in Europe: a look into the future.

Miravitlles M, Roche N, Cardoso J, Halpin D, Aisanov Z, Kankaanranta H, Kobližek V, Śliwiński P, Bjermer L, Tamm M, Blasi F, Vogelmeier CF.

Respir Res. 2018 Jan 18;19(1):11. doi: 10.1186/s12931-018-0715-1. Review.

46.

[Guideline for the Diagnosis and Treatment of Asthma - Guideline of the German Respiratory Society and the German Atemwegsliga in Cooperation with the Paediatric Respiratory Society and the Austrian Society of Pneumology].

Buhl R, Bals R, Baur X, Berdel D, Criée CP, Gappa M, Gillissen A, Greulich T, Haidl P, Hamelmann E, Kardos P, Kenn K, Klimek L, Korn S, Lommatzsch M, Magnussen H, Nicolai T, Nowak D, Pfaar O, Rabe KF, Riedler J, Ritz T, Schultz K, Schuster A, Spindler T, Taube C, Taube K, Vogelmeier C, von Leupold A, Wantke F, Weise S, Wildhaber J, Worth H, Zacharasiewicz A.

Pneumologie. 2017 Dec;71(12):e2. doi: 10.1055/s-0044-100881. Epub 2018 Jan 15. German. No abstract available.

PMID:
29334688
47.

The contribution of symptoms and comorbidities to the economic impact of COPD: an analysis of the German COSYCONET cohort.

Wacker ME, Kitzing K, Jörres RA, Leidl R, Schulz H, Karrasch S, Karch A, Koch A, Vogelmeier CF, Holle R.

Int J Chron Obstruct Pulmon Dis. 2017 Dec 4;12:3437-3448. doi: 10.2147/COPD.S141852. eCollection 2017.

48.

Prevalence of comorbidities in COPD patients by disease severity in a German population.

Greulich T, Weist BJD, Koczulla AR, Janciauskiene S, Klemmer A, Lux W, Alter P, Vogelmeier CF.

Respir Med. 2017 Nov;132:132-138. doi: 10.1016/j.rmed.2017.10.007. Epub 2017 Oct 12.

PMID:
29229085
49.

[Guideline for the Diagnosis and Treatment of Asthma - Guideline of the German Respiratory Society and the German Atemwegsliga in Cooperation with the Paediatric Respiratory Society and the Austrian Society of Pneumology].

Deutsche Gesellschaft für Arbeitsmedizin und Umweltmedizin e. V; Deutsche Gesellschaft für Rehabilitationswissenschaften e.V; und Deutsche Gesellschaft für Gynäkologie und Geburtshilfe e.V.;, Buhl R, Bals R, Baur X, Berdel D, Criée CP, Gappa M, Gillissen A, Greulich T, Haidl P, Hamelmann E, Kardos P, Kenn K, Klimek L, Korn S, Lommatzsch M, Magnussen H, Nicolai T, Nowak D, Pfaar O, Rabe KF, Riedler J, Ritz T, Schultz K, Schuster A, Spindler T, Taube C, Taube K, Vogelmeier C, von Leupoldt A, Wantke F, Weise S, Wildhaber J, Worth H, Zacharasiewicz A.

Pneumologie. 2017 Dec;71(12):849-919. doi: 10.1055/s-0043-119504. Epub 2017 Dec 7. German. Erratum in: Pneumologie. 2017 Dec;71(12 ):e2. Taube, R C [corrected to Taube, C]. Pneumologie. 2017 Dec;71(12):e3.

50.

Intensive smoking diminishes the differences in quality of life and exacerbation frequency between the alpha-1-antitrypsin deficiency genotypes PiZZ and PiSZ.

Bernhard N, Lepper PM, Vogelmeier C, Seibert M, Wagenpfeil S, Bals R, Fähndrich S.

Respir Med. 2017 Sep;130:1-8. doi: 10.1016/j.rmed.2017.07.004. Epub 2017 Jul 8.

PMID:
29206626

Supplemental Content

Loading ...
Support Center